Once-Weekly Semaglutide Formulations Effective and Safe for Indian Adults with Obesity
Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).
Background
Obesity is a growing global health crisis, significantly increasing the risk of numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. While Semaglutide, a GLP-1 receptor agonist, has demonstrated substantial efficacy in weight management across various populations, there remains a need for robust, region-specific data on its comparative efficacy and safety in diverse ethnic groups, particularly among Indian adults.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
